Trials / Completed
CompletedNCT05739292
Safety and Immunogenicity of Pentavalent Meningococcal Conjugate Vaccine (EuNmCV-5) in Healthy Adults Aged 19 to 55 Years Old
A Single Center, Randomized, Observer-blinded, Active Comparator Phase I Study to Assess the Safety and Immunogenicity of Meningococcal (Groups A, C, W-135, X and Y) Conjugate Vaccine in Healthy Adults Aged 19 to 55 Years Old
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- EuBiologics Co.,Ltd · Industry
- Sex
- All
- Age
- 19 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
Phase I study to evaluate safety and immunogenicity in healthy adult subjects following a single dose administration of Meningococcal (Group A, C, W-135, X, and Y)-CRM197 Conjugate vaccine
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | EuNmCV-5 | 0.5mL single intramuscular dose on Day 0 |
| BIOLOGICAL | Menveo | 0.5mL single intramuscular dose on Day 0 |
Timeline
- Start date
- 2023-02-28
- Primary completion
- 2023-05-10
- Completion
- 2023-10-04
- First posted
- 2023-02-22
- Last updated
- 2023-12-20
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05739292. Inclusion in this directory is not an endorsement.